Tamoxifen citrate. Chemical Name: 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate. Structural Formula: O H3C N CH3 CH3 CO2H CO2H OH CO2H Molecular Formula: C26H29NO.C6H807. Molecular Weight: 563.6 CAS Registry Number: 54965-24-1
Tamoxifen citrate is a white or almost white polymorphic, crystalline powder, slightly soluble in water, soluble in methanol and slightly soluble in acetone.
Absorption
Tamoxifen is absorbed from the gastrointestinal tract. However, the site and extent of absorption is not known. Peak serum levels of 15 to 25 nanogram/mL were observed three to six hours after administration of a single oral dose of tamoxifen 10 mg. Steady state serum levels are achieved after approximately 4 weeks therapy. Mean steady state values after dosing at 20mg twice daily were 285 +- 19 nanogram/mL and 477 +- 35 nanogram/mL for tamoxifen and N-desmethyltamoxifen, respectively.
Bioavailability
No information available.
Distribution
Little information is available on humans. It has been found in the uterus and ovary, particularly in the endometrium and corpus luteum. Radioactivity studies in animals show high levels in the liver, lung, ovary and spleen. Low levels have been found in the pituitary, eyes and brain.
Protein binding
The drug appears to be bound to an unknown degree to cytoplasmic protein receptors in all oestrogen target tissues, and is highly protein bound to serum albumin (>99%).
Metabolism
Tamoxifen undergoes extensive metabolism by hydroxylation, demethylation and conjugation, giving rise to several metabolites. The major circulating metabolite of tamoxifen in humans is N-desmethyltamoxifen which has a pharmacological profile very similar to that of tamoxifen and thus may contribute to therapeutic effect. Other minor metabolites are formed, some of which also have antioestrogenic activity.
Excretion
Elimination of tamoxifen and its major metabolite N-desmethyltamoxifen is slow. This leads to extensive accumulation of both compounds in serum during chronic administration. Tamoxifen is mainly excreted via the faeces, with only small amounts appearing in the urine. The drug is excreted mainly as conjugates. In one patient studied for 13 days after dosing, approximately 50% of the dose had been excreted in the faeces, and 13% in the urine. In animals, tamoxifen undergoes enterohepatic circulation, and is thought to do so in humans. In a clinical study where girls between 2 and 10 years with McCune Albright Syndrome (MAS) received 20 mg tamoxifen once a day for up to 12 months duration, there was an age-dependent decrease in clearance and an increase in exposure (AUC), (with values up to 50% higher in the youngest patients) compared with adults.
Half-life
The elimination half life of tamoxifen is estimated to be 5 to 7 days and 10 to 14 days for N- desmethyltamoxifen.
Clinical implications of pharmacokinetic data
Metabolism to active metabolites and the slow elimination of the drug and its metabolites implies accumulation of the drug with prolonged treatment. Its extensive hepatic metabolism means that dose may need to be decreased, or the dosing interval increased, in patients with liver disease.
Tamoxifen is a non-steroidal triphenylethylene based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an anti-oestrogen, preventing oestrogen binding to the oestrogen receptor.
Palliative treatment of breast cancer.
Tamoxifen must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment for breast cancer to exclude the possibility of pregnancy. Tamoxifen should not be given to patients who have experienced hypersensitivity to the product or any of its ingredients.
In a large randomised trial in Sweden of adjuvant tamoxifen 40 mg per day for 2 to 5 years, an increased incidence of uterine cancer was noted. 23 of 1,372 patients randomised to receive tamoxifen versus 4 of 1,357 patients randomised to the observation group developed cancer of the uterus {RR=5.6 (1.9-16.2, p<0.001}. One of the patients with cancer of the uterus who was randomised to receive tamoxifen never took the drug. After approximately 6.8 years of follow-up on the ongoing NSABP B-141 trial, 15 of 1,419 women randomised to receive tamoxifen 20 mg per day for 5 years developed uterine cancer and 2 of 1,424 women randomised to receive placebo, who subsequently had recurrent breast cancer and were treated with tamoxifen, also developed uterine cancer. Most of the uterine cancers were diagnosed at an early stage, but deaths from uterine cancer have been reported. Patients receiving tamoxifen should have routine gynaecological care and report any abnormal vaginal bleeding to their physician. In an uncontrolled trial in 28 girls aged 2-10 with McCune Albright Syndrome (MAS), who received 20mg once a day for up to 12 months duration, mean uterine volume increased after 6 months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established. Tamoxifen is not approved for treatment of McCune Albright Syndrome.1 In delayed microsurgical breast reconstruction tamoxifen may increase the risk of microvascular flap complications. Cases of visual disturbances, including infrequent reports of corneal changes, and common reports of retinopathy have been described in patients receiving tamoxifen therapy. Cataracts have commonly been reported in association with the administration of tamoxifen. Tamoxifen should be used cautiously in patients with existing leucopenia or thrombocytopenia. Leucopenia has been observed following the administration of tamoxifen sometimes in association with anaemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe and rarely cases of agranulocytosis have been reported. Decreases in platelet counts, usually between 50,000 and 100,000/mm3 (infrequently lower) have been occasionally reported in patients taking tamoxifen for breast cancer. Periodic complete blood counts, including platelet counts may be appropriate. A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported on clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear. Tamoxifen was not mutagenic in a range of in vitro and in vivo mutagenicity tests. Tamoxifen was genotoxic in some in vitro tests and in vivo genotoxicity tests in rodents. Gonadal tumours in mice and liver tumours in rats receiving tamoxifen have been reported in long term studies. The clinical relevance of these findings has not been established.
It should be noted that only a small number of premenopausal women have been treated, since candidates for therapy are usually postmenopausal, either reaching a natural menopause or having menopause induced by surgery or radiotherapy. Menstruation is suppressed in a proportion of
The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-14 trial is undergoing reaudit and information from this study may be subject to change.
premenopausal women receiving tamoxifen for the treatment of breast tumours. Cystic ovarian swellings have occasionally been observed in women receiving tamoxifen.
Tamoxifen must not be administered during pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken tamoxifen, although no causal relationship has been established. Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential. In rodent models of foetal reproductive tract development, tamoxifen was associated with changes similar to those caused by oestradiol, ethinyloestradiol, clomiphene and diethylstilboestrol. Although the clinical relevance of these changes is unknown, some of them, and especially vaginal adenosis, are similar to those seen in young women who were exposed to diethylstilboestrol in utero and who have a 1 in 1,000 risk of developing clear-cell carcinoma of the vagina or cervix. Only a small number of pregnant women have been exposed to tamoxifen. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed in utero to tamoxifen. Women should be advised not to become pregnant whilst taking tamoxifen and should use barrier or other non hormonal method of contraception if sexually active. Pre-menopausal women must be carefully examined before treatment to exclude pregnancy. Women should be informed of the potential risks to the foetus should they become pregnant whilst taking tamoxifen or within two months of cessation of therapy.
Category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed. Studies in animals have shown evidence of an increased occurrence of foetal damage, the significance of which is considered uncertain in humans.
It is not known if tamoxifen is excreted in human milk, and therefore, the drug is not recommended during lactation.
Tamoxifen is not indicated for use in children.
When tamoxifen is used in combination with coumarin type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration is initiated, careful monitoring of the patient is recommended. An increased risk of thromboembolic events may occur if tamoxifen is administered in combination with cytotoxic agents. The use of tamoxifen in combination with an aromatase inhibitor as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone. The known principal pathway for tamoxifen metabolism in humans is demethylation, catalysed by CYP3A4 enzymes. Pharmacokinetic interaction with CYP3A4 inducing agent rifampicin, showing a reduction in tamoxifen plasma levels has been reported in the literature. Pharmacokinetic interaction between CYP2D6 inhibitors and tamoxifen has been reported in the literature. This showed a reduction in plasma level of active tamoxifen metabolite, 4-hydroxy-N- desmethyltamoxifen. Reduced efficacy on tamoxifen has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine).
The adverse reactions which have been reported are of two types;
those associated specifically with the pharmacological action of the drug, e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae, tumour pain and tumour flare
those of a more general nature, e.g. gastrointestinal intolerance, headache light-headedness, skin rash and occasionally fluid retention and alopecia.
In patients treated with tamoxifen for metastatic breast cancer, the most frequent adverse reactions are hot flushes, nausea and vomiting. These may occur in up to one-fourth of patients. Less frequently reported adverse reactions are vaginal bleeding, vaginal discharge, menstrual irregularities, alopecia, and increased bone and tumour pain. Other adverse reactions that are seen infrequently are hypercalcaemia, peripheral oedema, pruritus vulvae, dizziness and lightheadedness. Infrequent cases of endometrial, ocular and haematological adverse effects have been reported (see PRECAUTIONS). When adverse reactions are severe, it may be possible to control them by a simple reduction in dosage (within the recommended dose range) without loss of control of the disease. If adverse reactions do not respond to this measure, it may be necessary to stop the treatment. There is evidence of ischaemic cerebrovascular events and thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism, occurring commonly during tamoxifen therapy. When tamoxifen is used in combination with cytotoxic agents, there is an increased risk of thromboembolic events occurring. Uncommonly, cases of interstitial pneumonitis have been reported. Skin rashes (including isolated reports of erythema multiforme, Stevens-Johnson syndrome and bullous pemphigoid) and commonly hypersensitivity reactions, including angioedema, have been reported. Although hypercalcaemia may occur in patients with advanced breast cancer, uncommonly patients with bony metastases have developed hypercalcaemia on initiation of therapy with tamoxifen. Uterine fibroids, endometriosis and other endometrial changes including hyperplasia and polyps have been reported. Cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen. Vaginal polyps have rarely been observed in women receiving tamoxifen. Tamoxifen has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis and hepatocellular injury (including hepatic necrosis). Commonly, elevation of serum triglyceride levels, in some cases with pancreatitis may be, associated with the use of tamoxifen. An increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen treatment. Cutaneous lupus erythematosus has been observed very-rarely in patients receiving tamoxifen. Porphyria cutanea tarda has been observed very-rarely in patients receiving tamoxifen. Cases of optic neuropathy and optic neuritis have been rarely reported in patients receiving tamoxifen and, in a small number of cases, blindness has occurred. Leg cramps and myalgia have been reported commonly in patients receiving tamoxifen. Sensory disturbances (including parasthesia and dysgeusia) have een reported commonly in patients receiving tamoxifen.
The recommended daily dose of tamoxifen is 20 mg. A dose of 40 mg once a day may be used in patients with advanced breast cancer in which no response is seen with the minimal dose. Tamoxifen is not indicated for use in children.
Tamoxifen is not indicated for use in children.
On theoretical grounds an overdosage would be expected to cause enhancement of the pharmacological side effects mentioned above. Observations in animals show that extreme overdosage (100 to 200 times the equivalent of the recommended daily human dose) may produce oestrogenic effects. There have been reports in the literature that tamoxifen given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.
There is no specific antidote to overdosage, and treatment must be symptomatic.
White, round, convex tablets, 9 mm in diameter with 20 embossed on one side. HDPE plastic bottles containing 60 tablets AUST R number 153122
are intended for oral administration. Each tablet contains tamoxifen citrate equivalent to 20 mg tamoxifen.
In addition, each tablet contains the following inactive ingredients: lactose, magnesium stearate, povidone, sodium starch glycollate, and maize starch. Store below 30degC. Protect from light.
Aspen Pharma Pty Ltd 34-36 Chandos Street St Leonards NSW 2065 Australia
Apotex Pty Ltd 16 Giffnock Avenue Macquarie Park, NSW 2113 Australia GenRx is a registered trade mark of Apotex Pty Ltd.
S4: Prescription Only Medicine.
23 February 2009